In fact, recent trials have shown that GLP-1 RA can reduce the risk of MACE in patients with type 2 diabetes and the progression of kidney diseases through a reduction in intraglomerular pressure, promoting natriuresis [40,41]. Here, GLP1R is linked to type 2 diabetes mellitus.